Analysis of treatment failure phenotype and prognostic factors of stage Ⅰ non-small cell lung cancer.
10.3760/cma.j.cn112152-20200605-00527
- Author:
Yu Jia SHEN
1
;
Xiao Long FU
1
Author Information
1. Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China.
- Publication Type:Review
- Keywords:
Non-small cell lung cancer;
Prognostic factor;
Stage Ⅰ;
Stereotactic body radiotherapy;
Surgical resection
- MeSH:
Carcinoma, Non-Small-Cell Lung/surgery*;
Humans;
Lung Neoplasms/pathology*;
Phenotype;
Prognosis;
Treatment Failure
- From:
Chinese Journal of Oncology
2022;44(3):219-227
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer (NSCLC) is one of the most severe malignant tumors worldwide. Lobectomy and systematic nodal dissection remain the standard treatment for stageⅠNSCLC. Stereotactic body radiotherapy (SBRT) has become the standard treatment for medically inoperable patients. Though the prognosis of stage Ⅰ NSCLC patients is generally good, there are still about 20% of patients with local recurrence and distant metastasis. There is significant heterogeneity in the prognosis and failure phenotype of patients, which cannot be precisely distinguished by the pathological TNM classification system. Identification of the risk factors for the prognosis of patients with stage Ⅰ NSCLC is a key step to realize the treatment from experience to precision. Screening the high-risk patients will facilitate to individually develop the adjuvant therapy strategy after surgery or SBRT and improve the overall curative effect. There are many factors that are significantly related to the prognosis of stage Ⅰ NSCLC including individual factors such as gender, age, and systemic inflammatory biomarkers; treatment-related factors such as the extent of surgical resection of the primary tumor and lymph nodes, the choice of different radiation rays, and different dose fractionation; and tumor-related factors such as imaging information, pathology information; and molecular biology information. This review will analyze the treatment failure phenotype and prognostic factors of stageⅠ NSCLC in various perspectives such as individual-, tumor- and treatment-related factors.
